JPMorgan Healthcare Leaders ETF (JDOC) has seen unusual trading volume, which is 24× higher than its average daily volume.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Among JDOC’s largest positions, Eli Lilly And Company is in focus after the drugmaker reported completion of a Phase 1 pediatric study for its experimental diabetes drug LY3209590 and drew fresh bullish commentary from Barclays, which reiterated a Buy rating and a $1,350 price target while calling the stock its top pharma pick ahead of an April 10 FDA decision on the weight-loss pill Orforglipron. Medtronic, another notable holding, also made headlines as Bank of America Securities maintained a Buy rating with a $110 price target, while the broader analyst consensus on the stock remains a Moderate Buy with meaningful upside from current levels.